Ramantamig
Stories
-
Janssen registers Ramantamig and Daratumumab versus DVRd trial in newly diagnosed multiple myeloma
The study, led by Janssen Research & Development, LLC, plans to enroll 1000 participants and is scheduled to start on December 14, 2026. It compares Ramantamig plus Daratumumab with the standard DVRd regimen followed by high-dose therapy, autologous stem cell transplant, and maintenance therapy.